Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

Achieving Excellence in Hepatitis B Virus Care for Veterans in the Veterans Health Administration.

Chartier M, Maier MM, Morgan TR, Lowy E, Hoffman-Högg L, Ross D, Beste LA.

Fed Pract. 2018 Mar;35(Suppl 2):S49-S53.

2.

Hepatitis A Virus Prevention and Vaccination Within and Outside the Veterans Health Administration in Light of Recent Outbreaks.

Moon AM, Lowy E, Maier MM, Chartier M, Morgan TR, Hoffman-Högg L, Beste LA.

Fed Pract. 2018 Mar;35(Suppl 2):S32-S37.

3.

Screening and Treating Hepatitis C in the VA: Achieving Excellence Using Lean and System Redesign.

Park A, Gonzalez R, Chartier M, Rogal S, Yakovchenko V, Ross D, Morgan TR.

Fed Pract. 2018 Jul;35(7):24-29.

4.

Will Studies in Nonalcoholic Steatohepatitis Help Manage Alcoholic Steatohepatitis?

Sundaram V, Morgan TR.

Clin Liver Dis. 2019 Feb;23(1):157-165. doi: 10.1016/j.cld.2018.09.008. Review.

PMID:
30454829
5.

The Veterans Affairs Hepatitis C Treatment Considerations.

Yee HS, Burton MJ, Belperio PS, Morgan TR.

Am J Gastroenterol. 2019 Feb;114(2):185-188. doi: 10.1038/s41395-018-0231-4. No abstract available.

PMID:
30315291
6.

Controversies in early liver transplantation for severe alcoholic hepatitis.

Wu T, Morgan TR, Klein AS, Volk ML, Saab S, Sundaram V.

Ann Hepatol. 2018 Aug 24;17(5):759-768. doi: 10.5604/01.3001.0012.3134.

7.

Is Granulocyte Colony Stimulating Factor a New Treatment for Alcoholic Hepatitis?

Morgan TR.

Clin Gastroenterol Hepatol. 2018 Oct;16(10):1564-1565. doi: 10.1016/j.cgh.2018.06.013. Epub 2018 Jun 18. No abstract available.

PMID:
29913276
8.

Hepatitis C Care in the Department of Veterans Affairs: Building a Foundation for Success.

Belperio PS, Chartier M, Gonzalez RI, Park AM, Ross DB, Morgan TR, Backus LI.

Infect Dis Clin North Am. 2018 Jun;32(2):281-292. doi: 10.1016/j.idc.2018.02.011. Review.

PMID:
29778256
9.

Corticosteroids Reduce Risk of Death Within 28 Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placebo-a Meta-analysis of Individual Data From Controlled Trials.

Louvet A, Thursz MR, Kim DJ, Labreuche J, Atkinson SR, Sidhu SS, O'Grady JG, Akriviadis E, Sinakos E, Carithers RL Jr, Ramond MJ, Maddrey WC, Morgan TR, Duhamel A, Mathurin P.

Gastroenterology. 2018 Aug;155(2):458-468.e8. doi: 10.1053/j.gastro.2018.05.011. Epub 2018 May 5.

PMID:
29738698
10.

Treatment of Alcoholic Liver Disease.

Morgan TR.

Gastroenterol Hepatol (N Y). 2017 Jul;13(7):425-427. No abstract available.

11.

The association between implementation strategy use and the uptake of hepatitis C treatment in a national sample.

Rogal SS, Yakovchenko V, Waltz TJ, Powell BJ, Kirchner JE, Proctor EK, Gonzalez R, Park A, Ross D, Morgan TR, Chartier M, Chinman MJ.

Implement Sci. 2017 May 11;12(1):60. doi: 10.1186/s13012-017-0588-6.

12.

Combined Sciatic and Lumbar Plexus Nerve Blocks for the Analgesic Management of Hip Arthroscopy Procedures: A Retrospective Review.

Jaffe JD, Morgan TR, Russell GB.

J Pain Palliat Care Pharmacother. 2017 Jun;31(2):121-125. doi: 10.1080/15360288.2017.1313355. Epub 2017 May 10.

PMID:
28489477
13.

Surgical implications and variability in the use of the flat epithelial atypia diagnosis on breast biopsy specimens.

Samples LS, Rendi MH, Frederick PD, Allison KH, Nelson HD, Morgan TR, Weaver DL, Elmore JG.

Breast. 2017 Aug;34:34-43. doi: 10.1016/j.breast.2017.04.004. Epub 2017 May 3.

14.

A Randomized Study Comparing Digital Imaging to Traditional Glass Slide Microscopy for Breast Biopsy and Cancer Diagnosis.

Elmore JG, Longton GM, Pepe MS, Carney PA, Nelson HD, Allison KH, Geller BM, Onega T, Tosteson AN, Mercan E, Shapiro LG, Brunyé TT, Morgan TR, Weaver DL.

J Pathol Inform. 2017 Mar 10;8:12. doi: 10.4103/2153-3539.201920. eCollection 2017.

15.

Race or genetic makeup for hepatitis C virus treatment decisions?

O'Brien TR, Kottilil S, Feld JJ, Morgan TR, Pfeiffer RM.

Hepatology. 2017 Jun;65(6):2124-2125. doi: 10.1002/hep.29057. Epub 2017 Apr 18. No abstract available.

16.

Vitamin D Status and Virologic Response to HCV Therapy in the HALT-C and VIRAHEP-C Trials.

Loftfield E, O'Brien TR, Pfeiffer RM, Howell CD, Horst R, Prokunina-Olsson L, Weinstein SJ, Albanes D, Morgan TR, Freedman ND.

PLoS One. 2016 Nov 10;11(11):e0166036. doi: 10.1371/journal.pone.0166036. eCollection 2016.

17.

Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection.

Rodriguez-Torres M, Lawitz E, Yangco B, Jeffers L, Han SH, Thuluvath PJ, Rustgi V, Harrison S, Ghalib R, Vierling JM, Luketic V, Zamor PJ, Ravendhran N, Morgan TR, Pearlman B, O'Brien C, Khallafi H, Pyrsopoulos N, Kong G, McPhee F, Yin PD, Hughes E, Treitel M.

Ann Hepatol. 2016 Nov-Dec 2016;15(6):834-845.

18.

Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities.

Ho SB, Monto A, Peyton A, Kaplan DE, Byrne S, Moon S, Copans A, Rossaro L, Roy A, Le H, Dvory-Sobol H, Zhu Y, Brainard DM, Guyer W, Shaikh O, Fuchs M, Morgan TR; VALOR study team.

Clin Gastroenterol Hepatol. 2017 Feb;15(2):282-288. doi: 10.1016/j.cgh.2016.05.024. Epub 2016 May 27.

PMID:
27237429
19.

Altitude Decompression Sickness Risk and Physical Activity During Exposure.

Webb JT, Morgan TR, Sarsfield SD.

Aerosp Med Hum Perform. 2016 Jun;87(6):516-20. doi: 10.3357/AMHP.4390.2016.

PMID:
27208673
20.

G Protection When Adding Pressurized Sleeves and Gloves to a Representative G-Suit Ensemble.

Morgan TR, Balldin U, Fischer JR.

Aerosp Med Hum Perform. 2016 May;87(5):464-9. doi: 10.3357/AMHP.4292.2016.

PMID:
27099085
21.

Identifying and processing the gap between perceived and actual agreement in breast pathology interpretation.

Carney PA, Allison KH, Oster NV, Frederick PD, Morgan TR, Geller BM, Weaver DL, Elmore JG.

Mod Pathol. 2016 Jul;29(7):717-26. doi: 10.1038/modpathol.2016.62. Epub 2016 Apr 8.

22.

Treatment of Severe Alcoholic Hepatitis.

Thursz M, Morgan TR.

Gastroenterology. 2016 Jun;150(8):1823-34. doi: 10.1053/j.gastro.2016.02.074. Epub 2016 Mar 4. Review.

23.

Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia.

Crabb DW, Bataller R, Chalasani NP, Kamath PS, Lucey M, Mathurin P, McClain C, McCullough A, Mitchell MC, Morgan TR, Nagy L, Radaeva S, Sanyal A, Shah V, Szabo G; NIAAA Alcoholic Hepatitis Consortia.

Gastroenterology. 2016 Apr;150(4):785-90. doi: 10.1053/j.gastro.2016.02.042. Epub 2016 Feb 24. No abstract available.

24.

Bacterial infections in cirrhosis.

Botwin GJ, Morgan TR.

Hepatol Int. 2014 Sep;8 Suppl 2:467-74. doi: 10.1007/s12072-014-9522-z. Epub 2014 Apr 18.

PMID:
26201326
25.

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, Sherman KE, Dretler R, Fishbein D, Gathe JC Jr, Henn S, Hinestrosa F, Huynh C, McDonald C, Mills A, Overton ET, Ramgopal M, Rashbaum B, Ray G, Scarsella A, Yozviak J, McPhee F, Liu Z, Hughes E, Yin PD, Noviello S, Ackerman P; ALLY-2 Investigators.

N Engl J Med. 2015 Aug 20;373(8):714-25. doi: 10.1056/NEJMoa1503153. Epub 2015 Jul 21.

26.

Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance.

O'Brien TR, Pfeiffer RM, Paquin A, Lang Kuhs KA, Chen S, Bonkovsky HL, Edlin BR, Howell CD, Kirk GD, Kuniholm MH, Morgan TR, Strickler HD, Thomas DL, Prokunina-Olsson L.

J Hepatol. 2015 Nov;63(5):1103-10. doi: 10.1016/j.jhep.2015.06.035. Epub 2015 Jul 15.

27.

A Phase II Randomized, Controlled Trial of S-Adenosylmethionine in Reducing Serum α-Fetoprotein in Patients with Hepatitis C Cirrhosis and Elevated AFP.

Morgan TR, Osann K, Bottiglieri T, Pimstone N, Hoefs JC, Hu KQ, Hassanein T, Boyer TD, Kong L, Chen WP, Richmond E, Gonzalez R, Rodriguez LM, Meyskens FL.

Cancer Prev Res (Phila). 2015 Sep;8(9):864-72. doi: 10.1158/1940-6207.CAPR-15-0029. Epub 2015 Jun 30.

28.

Combining Data From Liver Disease Scoring Systems Better Predicts Outcomes of Patients With Alcoholic Hepatitis.

Louvet A, Labreuche J, Artru F, Boursier J, Kim DJ, O'Grady J, Trépo E, Nahon P, Ganne-Carrié N, Naveau S, Diaz E, Gustot T, Lassailly G, Cannesson-Leroy A, Canva-Delcambre V, Dharancy S, Park SH, Moreno C, Morgan TR, Duhamel A, Mathurin P.

Gastroenterology. 2015 Aug;149(2):398-406.e8; quiz e16-7. doi: 10.1053/j.gastro.2015.04.044. Epub 2015 Apr 29.

PMID:
25935634
29.

Brief report: genetics of alcoholic cirrhosis-GenomALC multinational study.

Whitfield JB, Rahman K, Haber PS, Day CP, Masson S, Daly AK, Cordell HJ, Mueller S, Seitz HK, Liangpunsakul S, Westerhold C, Liang T, Lumeng L, Foroud T, Nalpas B, Mathurin P, Stickel F, Soyka M, Botwin GJ, Morgan TR, Seth D; GenomALC Consortium.

Alcohol Clin Exp Res. 2015 May;39(5):836-42. doi: 10.1111/acer.12693.

30.

A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectum.

Gillen DL, Meyskens FL, Morgan TR, Zell JA, Carroll R, Benya R, Chen WP, Mo A, Tucker C, Bhattacharya A, Huang Z, Arcilla M, Wong V, Chung J, Gonzalez R, Rodriguez LM, Szabo E, Rosenberg DW, Lipkin SM.

Cancer Prev Res (Phila). 2015 Mar;8(3):222-30. doi: 10.1158/1940-6207.CAPR-14-0148. Epub 2015 Jan 20.

31.

Corticosteroids can be used to treat alcoholic hepatitis after a recent upper gastrointestinal bleed.

Morgan TR.

J Hepatol. 2015 Apr;62(4):759-60. doi: 10.1016/j.jhep.2014.12.021. Epub 2014 Dec 25. No abstract available.

32.

Binge alcohol promotes hypoxic liver injury through a CYP2E1-HIF-1α-dependent apoptosis pathway in mice and humans.

Yun JW, Son MJ, Abdelmegeed MA, Banerjee A, Morgan TR, Yoo SH, Song BJ.

Free Radic Biol Med. 2014 Dec;77:183-94. doi: 10.1016/j.freeradbiomed.2014.08.030. Epub 2014 Sep 16.

33.

The inflammasome in alcoholic hepatitis: Its relationship with Mallory-Denk body formation.

Peng Y, French BA, Tillman B, Morgan TR, French SW.

Exp Mol Pathol. 2014 Oct;97(2):305-13. doi: 10.1016/j.yexmp.2014.08.006. Epub 2014 Aug 19.

34.

TLR3/4 signaling is mediated via the NFκB-CXCR4/7 pathway in human alcoholic hepatitis and non-alcoholic steatohepatitis which formed Mallory-Denk bodies.

Liu H, Li J, Tillman B, Morgan TR, French BA, French SW.

Exp Mol Pathol. 2014 Oct;97(2):234-40. doi: 10.1016/j.yexmp.2014.07.001. Epub 2014 Jul 2.

35.

Acceleration endurance with pressure breathing during G with and without a counterpressure vest.

Walker TB, Dart T, Morgan TR, Balldin UI.

Aviat Space Environ Med. 2014 Apr;85(4):401-6.

PMID:
24754200
36.

Update on recently approved treatments for hepatitis C.

Chao D, Botwin GJ, Morgan TR.

Curr Treat Options Gastroenterol. 2014 Jun;12(2):211-28. doi: 10.1007/s11938-014-0013-z.

PMID:
24648040
37.

Evaluation of fluid bolus administration rates using ruggedized field intravenous systems.

Morgan TR.

Wilderness Environ Med. 2014 Jun;25(2):204-9. doi: 10.1016/j.wem.2013.12.026. Epub 2014 Mar 13.

PMID:
24631229
38.

Acetyl-L-carnitine and lipoic acid improve mitochondrial abnormalities and serum levels of liver enzymes in a mouse model of nonalcoholic fatty liver disease.

Kathirvel E, Morgan K, French SW, Morgan TR.

Nutr Res. 2013 Nov;33(11):932-41. doi: 10.1016/j.nutres.2013.08.001. Epub 2013 Sep 18.

PMID:
24176233
39.

Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor.

Wang AS, Pfeiffer RM, Morgan TR, O'Brien TR.

Hepatology. 2014 Jun;59(6):2423-4. doi: 10.1002/hep.26771. Epub 2014 Apr 14. No abstract available.

40.

Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial.

Poordad F, Lawitz E, Reddy KR, Afdhal NH, Hézode C, Zeuzem S, Lee SS, Calleja JL, Brown RS Jr, Craxi A, Wedemeyer H, Nyberg L, Nelson DR, Rossaro L, Balart L, Morgan TR, Bacon BR, Flamm SL, Kowdley KV, Deng W, Koury KJ, Pedicone LD, Dutko FJ, Burroughs MH, Alves K, Wahl J, Brass CA, Albrecht JK, Sulkowski MS; Protocol 6086 Investigators.

Gastroenterology. 2013 Nov;145(5):1035-1044.e5. doi: 10.1053/j.gastro.2013.07.051. Epub 2013 Aug 4.

PMID:
23924660
41.

Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin.

Manns MP, Pockros PJ, Norkrans G, Smith CI, Morgan TR, Häussinger D, Shiffman ML, Hadziyannis SJ, Schmidt WN, Jacobson IM, Bárcena R, Schiff ER, Shaikh OS, Bacon B, Marcellin P, Deng W, Esteban-Mur R, Poynard T, Pedicone LD, Brass CA, Albrecht JK, Gordon SC.

J Viral Hepat. 2013 Aug;20(8):524-9. doi: 10.1111/jvh.12074. Epub 2013 Mar 3.

PMID:
23808990
42.

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus.

Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, Hergott D, Porter-Gill P, Mumy A, Kohaar I, Chen S, Brand N, Tarway M, Liu L, Sheikh F, Astemborski J, Bonkovsky HL, Edlin BR, Howell CD, Morgan TR, Thomas DL, Rehermann B, Donnelly RP, O'Brien TR.

Nat Genet. 2013 Feb;45(2):164-71. doi: 10.1038/ng.2521. Epub 2013 Jan 6.

43.

Alcoholic liver disease - Hepatocellular carcinoma transformation.

French SW, Lee J, Zhong J, Morgan TR, Buslon V, Lungo W, French BA.

J Gastrointest Oncol. 2012 Sep;3(3):174-81. doi: 10.3978/j.issn.2078-6891.2012.025. No abstract available.

44.

Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C.

Morishima C, Shiffman ML, Dienstag JL, Lindsay KL, Szabo G, Everson GT, Lok AS, Di Bisceglie AM, Ghany MG, Naishadham D, Morgan TR, Wright EC; HALT-C Trial Group.

Am J Gastroenterol. 2012 Sep;107(9):1388-98. doi: 10.1038/ajg.2012.137. Epub 2012 Jun 12.

45.

Factors that predict response of patients with hepatitis C virus infection to boceprevir.

Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR; SPRINT-2 and RESPOND-2 Investigators.

Gastroenterology. 2012 Sep;143(3):608-618.e5. doi: 10.1053/j.gastro.2012.05.011. Epub 2012 May 21.

PMID:
22626609
46.

Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office.

Yee HS, Chang MF, Pocha C, Lim J, Ross D, Morgan TR, Monto A; Department of Veterans Affairs Hepatitis C Resource Center Program; National Hepatitis C Program Office.

Am J Gastroenterol. 2012 May;107(5):669-89; quiz 690. doi: 10.1038/ajg.2012.48.

PMID:
22525303
47.

Management of Adverse Events During the Treatment of Chronic Hepatitis C Infection.

Nguyen DL, Morgan TR.

Clin Liver Dis (Hoboken). 2012 Apr;1(2):54-57. No abstract available.

48.

Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial.

Everson GT, Shiffman ML, Hoefs JC, Morgan TR, Sterling RK, Wagner DA, Lauriski S, Curto TM, Stoddard A, Wright EC; HALT-C Trial Group.

Hepatology. 2012 Apr;55(4):1019-29. doi: 10.1002/hep.24752. Epub 2012 Mar 1.

49.

Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C.

Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, Dienstag JL, Lok AS.

Am J Gastroenterol. 2012 Jan;107(1):64-74. doi: 10.1038/ajg.2011.312. Epub 2011 Sep 20.

50.

An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C.

O'Brien TR, Everhart JE, Morgan TR, Lok AS, Chung RT, Shao Y, Shiffman ML, Dotrang M, Sninsky JJ, Bonkovsky HL, Pfeiffer RM; HALT-C Trial Group.

PLoS One. 2011;6(7):e20904. doi: 10.1371/journal.pone.0020904. Epub 2011 Jul 8.

Supplemental Content

Loading ...
Support Center